Objectives: To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).
New data presented at the 2016 United European Gastroenterology (UEG) Week show that a switch to biosimilar infliximab (CT-P13)(Inflectra) from...
Celltrion Healthcare announced that the European Commission has approved Remsima SC (CT-P13 SC, biosimilar infliximab) for patients with RA. Remsima...
Objectives: To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy.
Objectives: To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Remsima ((CT-P13 SC, biosimilar infliximab) from Celltrion Healthcare Hungary Kft.
Results of an open-label extension study of Remsima/Inflectra (infliximab-biosimilar), from Hospira, in patients with Rheumatoid Arthritis, were presented at the...
Data announced by Pfizer and Celltrion Healthcare showed that for patients with moderate-to-severe Crohn's disease (CD), treatment with Inflectra (infliximab...
Epirus Pharma has announced data from their Phase III study of BOW 015 (infliximab-biosimilar), in patients with active Rheumatoid Arthritis...
Amgen announced results from a Phase III study evaluating the efficacy and safety of ABP 710 (infliximab biosimilar) compared with...